FOR IMMEDIATE RELEASE
Taiho Pharmaceutical Selects Medidata Rave for Global Trials
Japanese Specialty Pharmaceutical Implements Medidata Rave for Phase III Cancer Trials in Japan and South Korea
NEW YORK, N.Y. and TOKYO, JAPAN - July 28, 2008 – Medidata Solutions, a leading provider of clinical trial solutions, today announced that Taiho Pharmaceutical Co., Ltd. will implement Medidata Rave® as its electronic data capture (EDC), management and reporting solution of choice. Taiho Pharmaceutical, a specialty pharmaceutical company headquartered in Tokyo, plans to use Medidata Rave to conduct a Phase III trial for cervical cancer therapy in Japan and South Korea.
Established in 1963, Taiho Pharmaceutical is a developer focused on oncology, allergy, immunology and urology therapies. In March 2008, Taiho made the decision to evaluate a large number of EDC providers. After a rigorous vendor selection process, Taiho selected Medidata Rave due to the company’s impressive operational results in global, large-scale clinical trials as well as Medidata’s partnerships with leading CROs worldwide, specifically in South Korea.
“As a specialty pharma, we strive to adopt the most efficient and flexible solution in the industry that can address our global needs and enhance our processes in order to bring drugs to market quickly,” said Katsuhiko Sawada, Senior Manager for Clinical Data Management & Biostatistics, Clinical Support Department at Taiho Pharmaceutical. “Medidata’s sustained industry growth and leadership and global support team in Japan, as well as the company’s strong network of CRO partners, will enable an efficient implementation of Rave and allow us to increase our own operational results.”
Taiho anticipates that the company will effectively benefit from Medidata’s global CRO partners who also work with Taiho. Because these partners are familiar with the Rave EDC system, outsourcing studies to these CROs will enable faster study starts, smooth implementations, easier data transfer and compatibility during trials. Data managers can achieve further success through the creation of a global clinical trial process that is standardized on the Medidata Rave platform. Taiho also expects that investigators and data managers will experience reliability from the Rave system operations and Medidata’s training and professional staff services.
"We are delighted to welcome Taiho to our customer base in Japan, where clinical activity is expanding rapidly and sponsors continue to make investments in clinical technology," said Tarek Sherif, CEO of Medidata Solutions. "As we further extend our reach in the Asia-Pacific region through our customers and CRO partners, we will continue to benefit from relationships with companies like Taiho that share our vision of implementing and conducting the most efficient clinical trials on a global scale."
About Taiho Pharmaceutical Co., Ltd.
Since the foundation of Taiho Pharmaceutical Co., Ltd. in 1963, the company principle that “We will help to further human health and create a fulfilled society” has guided the company's ongoing research and development of innovative pharmaceuticals. We protect and nurture human lives, the irreplaceable, and precious lives are always in our fore. We remain a specialty pharma, not for the drug industry, but for the benefit of the people we serve. Humbly, and sometimes boldly with the spirit of challenge, we chart unexplored territories along the way. Taiho Pharmaceutical’s vision is a “global niche venture.” For more information, please visit www.taiho.co.jp/english/index.html.
About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com) is a leading provider of clinical trial solutions that enable the world’s most advanced life science organizations to maximize the value of their clinical research investments by putting powerful tools into researchers’ hands. A pioneer since 1999 in innovative technologies for planning and managing clinical studies – including protocol design; clinical data capture, management and reporting; and trial contracting and negotiation – Medidata Solutions and its global network of business partners address the unique needs of sponsors and sites of all sizes. With deep expertise in conducting studies across all phases and therapeutic areas, on six continents and in more than 80 countries, Medidata Solutions helps clinical researchers reduce trial cycle times, achieve early visibility to reliable clinical data, and maintain strict fiscal responsibility, while safely accelerating the process of bringing life-enhancing treatments to market.
Contact:
Susan McCarron
Lois Paul & Partners
781.782.5767
Susan_McCarron@lpp.com